Children exposed to antiretroviral (ARV) therapy in utero and not exposed to HIV showed no difference in language development ...

Kenya has the seventh-largest number of people living with HIV in the world, at around 1.4 million, according to World Health ...

Finance Minister Enoch Godongwana said that until a spending review is conducted on PEPFAR funded programmes, Treasury can't ...

Donald Trump’s 1987 bestseller, Trump: The Art of the Deal, includes this memory from when he was in elementary school: “I ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

A groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt cut in ...